id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-E-0142-0008,FDA,FDA-2004-E-0142,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Roche Palo Alto,Rule,Certificate Extending Patent Term,2007-04-23T04:00:00Z,2007,4,,,2025-11-19T00:57:08Z,,0,0,090000648046fe43
FDA-2004-E-0142-0007,FDA,FDA-2004-E-0142,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-09-07T04:00:00Z,2006,9,,,2025-11-19T00:49:49Z,,0,0,090000648046fe42
FDA-2004-E-0142-0005,FDA,FDA-2004-E-0142,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-06-19T04:00:00Z,2006,6,,,2025-11-19T00:41:41Z,,0,0,090000648046fe40
FDA-2004-E-0142-0006,FDA,FDA-2004-E-0142,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-06-19T04:00:00Z,2006,6,,,2025-11-19T00:47:17Z,,0,0,090000648046fe41
FDA-2004-E-0142-0004,FDA,FDA-2004-E-0142,Determination of Regulatory Review Period for Purposes of Patent Extension; ALOXI,Notice,General Notice,2006-02-02T05:00:00Z,2006,2,2006-02-02T05:00:00Z,,2025-11-19T00:36:35Z,06-903,0,0,090000648046fe3e
FDA-2004-E-0142-0003,FDA,FDA-2004-E-0142,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-01-11T05:00:00Z,2006,1,,,2025-11-19T00:32:14Z,,0,0,090000648046fe3d
FDA-2004-E-0142-0002,FDA,FDA-2004-E-0142,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-10-22T04:00:00Z,2004,10,,,2025-11-19T00:29:51Z,,0,0,090000648046fe3c
FDA-2004-E-0142-0001,FDA,FDA-2004-E-0142,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2004-09-02T04:00:00Z,2004,9,,,2025-11-24T21:41:02Z,,0,0,090000648046fe2c